Amneal Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 2014
Net Income	-168.69	-83.99	-129.99	10.62	91.06	-361.92	Upgrade
Depreciation & Amortization	226.78	229.4	240.18	233.41	235.39	207.24	Upgrade
Share-Based Compensation	25.95	26.82	31.85	28.41	20.75	21.68	Upgrade
Other Operating Activities	117.42	173.35	-76.94	-30.62	31.81	134.71	Upgrade
Operating Cash Flow	201.46	345.58	65.1	241.82	379	1.71	Upgrade
Operating Cash Flow Growth	138.50%	430.84%	-73.08%	-36.20%	22128.80%	-99.32%	Upgrade
Capital Expenditures	-45.46	-46.8	-48.8	-50.94	-61.84	-47.18	Upgrade
Acquisitions	0	0	-84.71	-146.54	-251.36	34.83	Upgrade
Other Investing Activities	-31.75	-22.39	-40.8	3.3	-4.35	-7.23	Upgrade
Investing Cash Flow	-77.21	-69.19	-174.31	-194.18	-317.55	-19.58	Upgrade
Share Issuance / Repurchase	0.48	0.45	0.66	0.85	0.32	1.4	Upgrade
Debt Issued / Paid	-0.07	22.65	-38.27	-79.18	142.99	-29.27	Upgrade
Other Financing Activities	-223.24	-235.68	-69.01	-59.8	-11.5	-17.96	Upgrade
Financing Cash Flow	-222.83	-212.57	-106.62	-138.12	131.81	-45.83	Upgrade
Exchange Rate Effect	-0.87	0.07	-5.68	0.1	1.04	-2.25	Upgrade
Net Cash Flow	-99.45	63.88	-221.51	-90.38	194.3	-65.96	Upgrade
Free Cash Flow	155.99	298.78	16.31	190.88	317.17	-45.48	Upgrade
Free Cash Flow Growth	322.10%	1732.42%	-91.46%	-39.82%	-	-	Upgrade
Free Cash Flow Margin	6.25%	12.48%	0.74%	9.12%	15.92%	-2.80%	Upgrade
Free Cash Flow Per Share	0.51	1.70	0.11	1.28	2.15	-0.34	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).